Latest From Genmab AS
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
The latest drug development news and highlights for our US FDA Performance Tracker.
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genmab AS
- Senior Management
Jan van de Winkel, PhD, Pres. & CEO
David A Eatwell, EVP, CFO
Judith Klimovsky, MD, EVP, Chief Dev. Officer
- Contact Info
Phone: (45) 7020 2728
Kalvebod Brygge 43
Copenhagen, 1560 V
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.